#USA #Nashville #OneOncology #OneR #ASCO2025

OneOncology and OneR Share Innovations at ASCO 2025

The American Society of Clinical Oncology (ASCO) Annual Meeting 2025 is set to be a landmark event as physicians from OneOncology partner practices and the OneOncology Research Network (OneR) present 23 compelling research abstracts. Scheduled from May 30 to June 3, 2025, this year’s presentations underscore the critical advancements and emerging therapies that are evolving in the realm of oncology.

Driven by a commitment to enhancing cancer care across community practices, these abstracts delve into a wide spectrum of cancer treatments, notably focusing on areas such as lymphoma, lung cancer, and the management of rare tumors. Notably, two studies from OneR have received the prestigious title of “Best of ASCO,” highlighting their potential to revolutionize practice and treatment protocols.

Pioneering Research and Its Implications

Among the standout research findings, one study showcases the early results of mosunetuzumab, an innovative injectable treatment specifically designed for patients battling high-risk follicular lymphoma. This emerging therapy promises to alter the trajectory of treatment for many patients, offering new hope in combating this challenging form of cancer. Additionally, long-term results from a study involving zanubrutinib—a targeted therapy for chronic lymphocytic leukemia—demonstrate significant improvements in patient outcomes, particularly for individuals with high-risk genetic profiles, such as 17p deletions.

Ian Flinn, MD, PhD, the Chief Scientific Officer at OneOncology, expressed enthusiasm about the growing research footprint at ASCO, stating that these findings not only represent significant advancements in oncology but also bring a renewed sense of hope for patients seeking improved treatment options. "These studies reflect the strength of science throughout independent community-based practices," Flinn noted. He emphasized that the inclusivity of these clinical trials enhances access to cutting-edge treatments for patients, allowing them to benefit from innovations much closer to home than previously possible.

Fostering Community Engagement in Research

OneR’s role as a national site management organization is pivotal in enabling effective multi-center clinical research across its network of independent oncology practices. This connection of top-tier investigators, clinical trials, and real-world data facilitates a network where patients can access the latest in cancer care innovations.

The 23 abstracts represent both fundamental insights into innovative treatments and a multi-faceted approach to making clinical trials more accessible for patients across diverse backgrounds. The outcomes not only catalyze further research but also establish a significant precedent for community oncology practices nationwide, showing that impactful research can and does emerge from independent settings, not just academic institutions.

The comprehensive list of abstracts presented by OneOncology and OneR is available for those seeking in-depth knowledge about these vital studies. For professional inquiries, interviews with OneR representatives during the ASCO event can be arranged by reaching out to Eric Hoffman.

About OneOncology

Founded by community oncologists for their fellow practitioners, OneOncology’s mission is clear: to enhance the quality of life for all individuals living with cancer. Supporting community oncology practices through various initiatives such as operational optimization, data analytics, and clinical innovations, OneOncology is committed to ensuring that patient care remains localized and cost-effective. Currently, the organization encompasses approximately 1,750 cancer care providers who deliver care to about one million patients across over 565 sites nationwide. For more information, visit OneOncology's website or follow their updates on LinkedIn.